Tisch MS Research Center of New York (Tisch MSRCNY) announced recently that it has been awarded a $1 million research grant from the National MS Society to support Phase II of their FDA-Approved Stem Cell Clinical Trial for MS.
Phase I of this trial was completed in 2017 with published results showing safety and tolerability, as well as encouraging efficacy trends.
“We are deeply appreciative for this support from the National MS Society as we initiate Phase II of this study to hopefully establish the effectiveness of our stem cell treatment. Together, we are on the forefront in forming the therapeutic basis of reversing disability in people with MS,” said Dr. Saud A. Sadiq, Director and Chief Research Scientist at Tisch MSRCNY.
The Phase II trial is a randomized, placebo-controlled, double-blind study testing the efficacy of multiple intrathecal injections of autologous bone marrow-derived mesenchymal stem cell neural progenitors (MSC-NP) in 50 patients with progressive MS. Additional funding needs to be secured to ensure completion of the 3-year study.
About Tisch MS Research Center of New York (Tisch MSRCNY)
The Tisch MS Research Center of New York is an independent nonprofit 501(c)(3) organization dedicated to finding the cause of and cure for multiple sclerosis. By conducting groundbreaking medical investigations, Tisch MSRCNY accelerates the pace at which research discoveries translate from lab bench to bedside. The Center aims to discover the cause of MS, understand disease mechanism, optimize therapies, and repair the damage caused by MS while offering patient access to the best and most advanced treatment possible.
Article courtesy of Tisch MSRCNY.